Skip to content

Targeting Insomnia to Prevent Depression in the Menopause Transition

Targeting Insomnia to Prevent Depression in the Menopause Transition

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07443644
Enrollment
230
Registered
2026-03-02
Start date
2026-09-01
Completion date
2031-02-01
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia, Menopause Related Conditions

Keywords

menopause, hot flashes, cognitive behavioral therapy for insomnia, insomnia

Brief summary

This randomized clinical trial is focused on perimenopausal women who have difficulty sleeping. It will randomize digital cognitive behavioral therapy for insomnia (dCBT-I) or a sleep hygiene intervention (SHI). After treatment, participants will be assessed every 3-months over a 2-year period. The two main questions the study aims to answer are: 1. Do participants receiving dCBT-I experience less severe depressive symptoms compared with sleep hygiene (SH) over 2 years of study participation? 2. Are the effects of dCBT-I on depressive symptom severity mediated by an improvement in insomnia symptoms?

Detailed description

Insomnia is a common problem for women in perimenopause. Previous research found that insomnia predicts future development of depression and suggests that treating insomnia can lead to improvement in mood. This study will investigate the long-term effects of treating insomnia with two different interventions on depression among perimenopausal individuals. The two interventions are, digital cognitive behavioral therapy for insomnia (dCBT-I), which has been proven effective, and sleep hygiene intervetion (SHI), which is in common use in general practice. Participants will be screened for eligibility. Those eligible will be randomized to one of the two treatment arms (dCBT-I or SHI) and complete assessments at 3-month intervals across a 2-year period. Assessments will include questionnaires, clinical interviews, and using a wearable device. All assessments will be done remotely. Aim 1: To determine if dCBT-I in the menopause transition prospectively prevents depressive symptoms and improves menopause-specific quality of life. Aim 2: To determine whether the effect of dCBT-I on depressive symptoms is mediated through improving insomnia symptom severity (primary) and secondarily, reducing wakefulness after sleep onset in the menopause transition. The study will also explore pathways linking dCBT-I and prevention of depressive symptoms.

Interventions

A digital CBT-I program that includes stimulus control, sleep restriction therapy, and cognitive therapy

A digital sleep hygiene education intervention that includes recommendations about environmental and behavioral factors that can support healthy sleep.

Sponsors

SRI International
Lead SponsorINDUSTRY
Stanford University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. At least 40 years old and in the perimenopause, 2. Willingness to participate in a digital research protocol, 3. Current moderate to severe insomnia symptoms that started or worsened in association with perimenopause, 4. English fluency.

Exclusion criteria

1. Current major depressive disorder 2. Existing diagnosis of a sleep disorder other than insomnia 3. Experiencing excessive daytime sleepiness 4. Having received CBT-I in the preceding 6 months 5. Severe psychiatric or medical conditions or medications that could compromise safe participation in the study or interfere with the scientific aims 6. Hysterectomy and/or bilateral ovariectomy or current hormonal therapy, 7. Night shift worker

Design outcomes

Primary

MeasureTime frameDescription
Depressive symptom severity (PHQ-9 score)Baseline and every 3 months post randomization for 2 years
Insomnia severity index (ISI)Baseline and every 3 months post-randomization for 2 yearsScore on the insomnia severity index

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026